Ken Fisher Ideaya Biosciences, Inc. Transaction History

Fisher Asset Management, LLC

$227 Billion
Q1 2025

A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Fisher Asset Management, LLC holds 965,031 shares of IDYA stock, worth $22.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

965,031

Previous 876,599 10.09%

Holding current value

$22.8 Million

Previous $22.5 Million 29.83%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$16.38 - $26.0 $1.45 Million - $2.3 Million	88,432 Added 10.09%	965,031 $15.8 Million
Q4 2024 Feb 05, 2025	BUY	$24.79 - $31.98 $686,435 - $885,526	27,690 Added 3.26%	876,599 $22.5 Million
Q3 2024 Nov 12, 2024	BUY	$30.37 - $43.05 $5.44 Million - $7.71 Million	179,114 Added 26.74%	848,909 $26.9 Million
Q2 2024 Aug 14, 2024	SELL	$34.37 - $43.46 $15,810 - $19,991	-460 Reduced 0.07%	669,795 $23.5 Million
Q1 2024 May 09, 2024	BUY	$34.2 - $47.13 $4.47 Million - $6.15 Million	130,579 Added 24.2%	670,255 $29.4 Million
Q4 2023 Mar 05, 2024	BUY	$24.59 - $35.83 $16,008 - $23,325	651 Added 0.12%	539,676 $19.2 Million
Q4 2023 Feb 06, 2024	BUY	$24.59 - $35.83 $12.5 Million - $18.2 Million	507,500 Added 1609.83%	539,025 $19.2 Million
Q3 2023 Nov 13, 2023	SELL	$21.07 - $29.77 $362,951 - $512,818	-17,226 Reduced 35.33%	31,525 $850,000
Q2 2023 Dec 12, 2023	BUY	$13.33 - $25.53 $229,622 - $439,779	17,226 Added 54.64%	48,751 $1.15 Million
Q2 2023 Aug 08, 2023	BUY	$13.33 - $25.53 $649,850 - $1.24 Million	48,751 New	48,751 $1.15 Million

Others Institutions Holding IDYA

# of Institutions

216

Shares Held

80M

Call Options Held

80.3K

Put Options Held

30.5K

View Full List

About IDEAYA Biosciences, Inc.

Ticker IDYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,067,700
Market Cap $1.13B
Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...

More about IDYA

Track Ken Fisher's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.

Account